Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 6/20 | 0.42 |
| ▸ | EIF4E | P06730 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | IL2 | P60568 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3747340 | 0.91 | KDM4E (0.44) | MRGPRX4EIF4EKDM4EUSP2ALDH1A1 | |
| SCHEMBL3750445 | 0.87 | EIF4E (0.43) | EIF4EKDM4EALDH1A1HPGDSCN9A | |
| SCHEMBL3754181 | 0.85 | PLG (0.43) | EIF4EKDM4E | |
| SCHEMBL3755130 | 0.84 | KMO (0.44) | EIF4EKDM4EALDH1A1HPGD | |
| SCHEMBL3747206 | 0.83 | ALK (0.38) | HPGDSCN9AALKIL2 | |
| SCHEMBL3757989 | 0.81 | MRGPRX4 (0.41) | MRGPRX4EIF4ESCN9A | |
| SCHEMBL3752815 | 0.81 | KMO (0.40) | MRGPRX4KDM4EALDH1A1HPGD | |
| SCHEMBL3753505 | 0.80 | ALDH1A1 (0.43) | EIF4EKDM4EALDH1A1HPGD | |
| SCHEMBL3762159 | 0.79 | KDM4E (0.42) | MRGPRX4EIF4EKDM4EHPGD | |
| SCHEMBL3754215 | 0.79 | KDM4E (0.40) | EIF4EKDM4EALDH1A1HPGDSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | NAPRT, PNPO, FABP3 | MRGPRX4 4532/4885EIF4E 3817/4885KDM4E 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.